These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Pfreundschuh M; Schubert J; Ziepert M; Schmits R; Mohren M; Lengfelder E; Reiser M; Nickenig C; Clemens M; Peter N; Bokemeyer C; Eimermacher H; Ho A; Hoffmann M; Mertelsmann R; Trümper L; Balleisen L; Liersch R; Metzner B; Hartmann F; Glass B; Poeschel V; Schmitz N; Ruebe C; Feller AC; Loeffler M; Lancet Oncol; 2008 Feb; 9(2):105-16. PubMed ID: 18226581 [TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of concordant and discordant cytomorphology of bone marrow involvement in patients with diffuse, large, B-cell lymphoma treated with R-CHOP. Shim H; Oh JI; Park SH; Jang S; Park CJ; Huh J; Suh C; Chi HS J Clin Pathol; 2013 May; 66(5):420-5. PubMed ID: 23610041 [TBL] [Abstract][Full Text] [Related]
26. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]. Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686 [TBL] [Abstract][Full Text] [Related]
27. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Pfreundschuh M; Trümper L; Osterborg A; Pettengell R; Trneny M; Imrie K; Ma D; Gill D; Walewski J; Zinzani PL; Stahel R; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Lehtinen T; López-Guillermo A; Corrado C; Scheliga A; Milpied N; Mendila M; Rashford M; Kuhnt E; Loeffler M; Lancet Oncol; 2006 May; 7(5):379-91. PubMed ID: 16648042 [TBL] [Abstract][Full Text] [Related]
28. Composite T lymphoblastic leukemia/lymphoma and diffuse large B-cell lymphoma: case report. Niino D; Ohsaki K; Arakawa F; Watanabe J; Kimura Y; Kiyasu J; Takeuchi M; Miyoshi H; Yoshida M; Sugita Y; Ohshima K; Okamura T Pathol Int; 2011 Jun; 61(6):363-8. PubMed ID: 21615612 [TBL] [Abstract][Full Text] [Related]
29. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era. Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321 [TBL] [Abstract][Full Text] [Related]
30. Intravascular large B-Cell lymphoma with bone marrow involvement and superior sagittal sinus thrombosis: report of a case successfully treated with a CHOP/rituximab combination regimen. Jardin F; Callonnec F; Contentin N; Picquenot JM; Gueit I; Héron F; Bastard C; Tilly H Clin Lymphoma; 2005 Jun; 6(1):46-9. PubMed ID: 15989707 [TBL] [Abstract][Full Text] [Related]
31. Successful treatment of gastrointestinal follicular lymphoma with rituxan and combination chemotherapy. Al-Salman J; Salib H; Boonswang P Med Oncol; 2001; 18(4):277-83. PubMed ID: 11918454 [TBL] [Abstract][Full Text] [Related]
32. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W; Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325 [TBL] [Abstract][Full Text] [Related]
33. Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab. Hiraga J; Tomita A; Suzuki N; Takagi Y; Narita M; Kagami Y Ann Hematol; 2018 Nov; 97(11):2253-2255. PubMed ID: 29725760 [No Abstract] [Full Text] [Related]
34. 5-Azacytidine partially restores CD20 expression in follicular lymphoma that lost CD20 expression after rituximab treatment: a case report. Tsutsumi Y; Ohigashi H; Ito S; Shiratori S; Teshima T J Med Case Rep; 2016 Feb; 10():27. PubMed ID: 26838941 [TBL] [Abstract][Full Text] [Related]
35. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Nowakowski GS; LaPlant B; Habermann TM; Rivera CE; Macon WR; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Klebig RR; Reeder CB; Witzig TE Leukemia; 2011 Dec; 25(12):1877-81. PubMed ID: 21720383 [TBL] [Abstract][Full Text] [Related]
36. Primary cutaneous follicle center cell lymphoma of the scalp successfully treated with anti CD20 monoclonal antibody and CHOP combination therapy with no subsequent permanent loss of hair. Imai Y; Isoda K; Ito E; Hakamada A; Yamanishi K; Mizutani H J Dermatol; 2003 Sep; 30(9):683-8. PubMed ID: 14578559 [TBL] [Abstract][Full Text] [Related]
37. [Clinicopathologic features of lymphoplasmacytic lymphoma]. Liu EB; Zhang PH; Li ZQ; Sun Q; Yang QY; Fang LH; Sun FJ; Qiu LG Zhonghua Bing Li Xue Za Zhi; 2010 May; 39(5):308-12. PubMed ID: 20654153 [TBL] [Abstract][Full Text] [Related]
38. New treatment options have changed the survival of patients with follicular lymphoma. Fisher RI; LeBlanc M; Press OW; Maloney DG; Unger JM; Miller TP J Clin Oncol; 2005 Nov; 23(33):8447-52. PubMed ID: 16230674 [TBL] [Abstract][Full Text] [Related]
40. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study. Martin P; Byrtek M; Dawson K; Ziemiecki R; Friedberg JW; Cerhan JR; Flowers CR; Link BK Cancer; 2013 Dec; 119(23):4129-36. PubMed ID: 24006156 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]